The Size of the Next-Generation Antibody Therapeutics Market in Latin America is valued at USD 0.54 billion in 2023 and is projected to grow at a CAGR of 8% to reach USD 0.79 billion by 2028 during the forecast period 2023 to 2028.
Growth in the Latin America next-generation antibody therapies market is predicted to be driven by Y-O-Y growth in the prevalence of cancer, technological improvements, and a growing elderly population across the continent.
Growing investments from biopharmaceutical and pharmaceutical firms in developing effective antibodies to treat diseases, including autoimmune, inflammatory, and chronic diseases, will likely drive the market's growth rate. In addition, the global population of people over 65 years old is rapidly increasing, likely to boost demand for next-generation antibody treatments in this region over the projection period.
The market for next-generation antibody treatments in Latin America is being boosted by increasing the incidence of diseases such as cancer and asthma. According to the Asthma and Allergy Foundation of America (AAFA), asthma affects approximately 25 million Americans or 1 in every 13 people. Year after year, the numbers keep rising. Another essential element driving the Latin American next-generation antibody therapies industry is the growing discovery and development of monoclonal antibodies.
Furthermore, technical developments increased R&D efforts, and government funding and expenditures in the antibody therapeutics industry support market expansion. These factors are predicted to drive the Latin America Next-Generation Antibody Therapeutics Market during the forecast period.
One of the main factors impeding the next-generation antibody therapeutics market's growth is the high prices involved with an antibody treatment.
The market for next-generation antibody therapeutics in Latin America is projected to be hampered by the complexities connected with rigorous regulatory procedures for producing pharmaceuticals. In addition, the market is also believed to be hindered by a lack of knowledge among patients.
Therapeutic antibodies have functional limitations, such as poor pharmacokinetics and tissue accessibility and compromised immune system interactions. These flaws indicate areas where more research is needed.
They could not be used in antigen cross-linking experiments like hem agglutination because small changes to the antibody's binding site influence the antibody's binding site.
This research report on the Latin America Next-Generation Antibody Therapeutics Market has been segmented and sub-segmented into the following categories
By Therapeutics:
By Technology:
By Country:
Geographically, the Latin America Next-Generation Antibody Therapeutics Market is expected to rise steadily over the forecast period because of the growing aging population, urbanization, and lifestyle changes.
The enormous success of monoclonal antibody discovery and its development first fuelled the growth of next-generation antibody treatments in this field. With discoveries and therapeutic applications of next-generation antibodies, researchers will continue to push the Next-Generation Antibody Therapeutics market forward in the Latin American region. In addition, the growing frequency of chronic diseases will further drive the demand for next-generation antibody therapies.
The Brazil's next-generation antibody therapeutics market is expected to lead the Latin American market for Next-Generation Antibody Therapeutics. In the antibody therapies sector, governments are expanding funding and grants for research. This, together with rising healthcare expenditures in both developed and developing countries, will help drive the market expansion throughout the projection period.
The Mexico next-generation antibody therapeutics market is likely to account for a sizable portion of the Latin American market for Next-Generation Antibody Therapeutics. In addition, many significant pharmaceuticals, biotechnology, and biopharmaceutical companies are investing in developing next-generation therapeutic antibodies for autoimmune illnesses, inflammatory disorders, and malignancies. These strong drivers will support a rapidly growing market during the projection period.
KEY MARKET PLAYERS
Noteworthy Companies leading the Latin America Next-Generation Antibody Therapeutics Market profiled in the report are Takeda, Dyax Corp., Immunogen, Biogen, Kyowa Hakko Kirin Co., Ltd., Roche, Seattle Genetics, Amgen, Inc., AstraZeneca, Pfizer, Inc., and Xencor, Inc.,
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1200
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region